Sobre nosotros Fuda Cancer Hospital

Guangzhou Fuda Cancer Hospital

Under the administration of the Health Commission of Guangdong Province, Guangzhou Fuda Cancer Hospital is an international-oriented oncology-specialized hospital integrating medical care, teaching, scientific research, disease prevention and healthcare. Guided by high and new technologies, it features minimally invasive therapies, and is the first oncology-specialized hospital in Guangdong Province accredited by Joint Commission International (JCI). The hospital consists of the Tianhe Campus and Haizhu Campus, with a total floor area of over 30,000 m², 400 open beds and 45 VIP rooms.

In 2010, the former Ministry of Health designated FUDA Cancer Hospital as one of the first batch of National Key Clinical Cancer Speciality Centres (Oncology). In 2017, the Hospital was awarded the title of Civilized Unit of Guangdong Province. In 2018, the Hospital was officially accredited as a National Key Clinical Specialty (Oncology). In 2019, the Hospital was named a High-level Key Clinical Cancer Speciality Centre of Guangdong Province (Oncology). In 2021, the Hospital Party Committee was conferred the honorary title of Advanced Grassroots Party Organization of Guangdong Province. The Hospital has received multiple honors including National Trustworthy Private Hospital and Top-100 National Trustworthy Demonstration Hospital for the Public. It is a designated medical institution for nationwide inter-provincial on-the-spot medical insurance settlement, a designated unit for provincial-level and municipal-level public-funded medical care of Guangdong, as well as a designated hospital under Guangzhou Municipal Medical Insurance Scheme.

Upholding its hospital motto “Practising medicine with great virtue; advancing medical ethics in solidarity”, and adhering to the hospital-running guidelines “Prospering the hospital through science and technology, sustaining the hospital through integrity, operating the hospital with benevolence”, the hospital pursues a development path of high-end positioning, academic emphasis and international outreach. It has developed the distinctive 3C+P Model of comprehensive personalized care, consisting of Cryo-Irreversible Electroporation Ablation (CIA), Cancer Vascular Intervention (CVI), and Combined Immunotherapy for Cancer (CIC), plus Personalized (P) comprehensive therapy. Patients from more than 130 countries and regions worldwide have been attracted to come, 60 % of whom are from Southeast Asia, the Middle East, Europe and North America.

Guangzhou Fuda Cancer Hospital fosters an institutional culture of “Shouldering responsibilities and devoting to public welfare”, and has long been committed to social welfare initiatives. The hospital has donated funds and supplies for disaster-stricken areas such as the Wenchuan and Ya’an earthquakes, taken part in public-benefit programmes including “Caring-for-People Charity Campaign of Guangzhou”, and established the Fuda Benevolence Foundation. Cumulative donations of funds and materials have exceeded RMB 20 million over the years. The Hospital has provided free physical examinations for more than 10,000 nearby elderly persons living alone. Through community free clinics, health lectures, financial assistance for impoverished patients and other outreach activities, it delivers tangible benefits to the general public and earnestly fulfils its social responsibilities.
🎓
Equipo de clase mundial
Graduados de universidades líderes a nivel mundial
🔬
I+D avanzada
Desarrollado internamente
🤖
Enfoque en innovación
Múltiples tecnologías innovadoras

Galería de la empresa

Problemas de la industria abordados

locally unresectable tumors, systemic metastasis, need to reduce systemic toxicity or preserve organ function with less invasive options

Healthcare - Hospital (Oncology specialty)

locally unresectable tumors, systemic metastasis, need to reduce systemic toxicity or preserve organ function with less invasive options

Impacto: Business impact: for hospital—drives development of minimally invasive, interventional and immunotherapies and attracts international patients; for patients—more organ‑sparing, lower‑toxicity and life‑prolonging options.
Segmento: Oncology specialty care and international patient services

Definiciones de servicio

Comprehensive oncology services (cryoablation, NanoKnife, interventional, chemo/radiotherapy, immunotherapy)

Comprehensive oncology services (cryoablation, NanoKnife, interventional, chemo/radiotherapy, immunotherapy)

Medical services: oncology specialty clinical care, minimally invasive interventional treatments, immuno‑/cell therapies, rehabilitation and supportive care

Duración: Service cycle: varies widely by disease and plan—from single‑session interventions to long‑term systemic therapy and follow‑up; durations range from days to months or longer and require case‑by‑case confirmation.
Modo: Delivery: primarily on‑site outpatient/inpatient treatment; initial remote consultations and assessments offered via online appointment and tele‑evaluation.

Capacidades de servicio

Capability

Capacidades de servicio

Experiencia principal: Core expertise: clinical application of cryoablation, IRE (NanoKnife), vascular interventional oncology and combined immunotherapy
Experiencia: 20 Años
Idiomas: English, Thai, Indonesian, Malay, Russian, Kazakh, Mongolian, Chinese, Cantonese

Soluciones de servicio

3C+P Personalized Comprehensive Oncology Solution (Cryo-NanoKnife, Vascular Intervention,  Combined Immunotherapy + Personalization)

3C+P Personalized Comprehensive Oncology Solution (Cryo-NanoKnife, Vascular Intervention, Combined Immunotherapy + Personalization)

Descripción general: Overview: core of cryoablation, Nanoknife, vascular interventional oncology and combined immunotherapy, integrated with molecular testing and MDT for personalized plans
Características: Core features: multidisciplinary individualized decisions, combined minimally invasive ablation technology, international patient care and research support

Metodologías de servicio

MDT-led personalized 3C+P treatment methodology

MDT-led personalized 3C+P treatment methodology

Framework: MDT assessment → molecular/imaging diagnostics → personalized combined treatments (cryo/nanoknife/intervention/immuno/chemo-radio) → rehab & follow-up

Procesos de servicio

Nombre del proceso Descripción del proceso Pasos clave Cronograma Entregables
Patient pathway: Consultation → MDT → Treatment → Follow-up Overview: online/phone appointment → outpatient assessment → imaging/molecular tests → MDT plan → treatment → rehab & follow-up - - -

Casos de servicio

Estudio de caso

Industria del cliente: Individual patient (medical/international patient case)

Estudio de caso

Industria del cliente: Case patient background: vehicle mechanic from Guangxi

Estudio de caso

Industria del cliente: Patient is a student (case individual), not an industry client

Estudio de caso

Industria del cliente: Patient (healthcare recipient)

Estudio de caso

Industria del cliente: Patient family from the catering industry (case detail)

Rendimiento del servicio

📊
Metric names: JCI accreditation, National Clinical Key Specialty designation, number of beds
50%
Definition: JCI denotes compliance with international patient safety & quality standards; bed count reflects capacity
Measurement period: depends on the metric (not specified on site)
Referencia: Benchmark: peer JCI-accredited and national clinical key specialty oncology hospitals

Videos de la empresa y productos

Introducción a la empresa y tour por la fábrica

⏱ Duration: 3:45 | 👁 Views: 15,230

Demostración del producto - Kestrel K-1

⏱ Duration: 5:12 | 👁 Views: 28,450

showcase de innovación tecnológica

⏱ Duration: 4:30 | 👁 Views: 12,890

Testimonios de clientes y casos de éxito

⏱ Duration: 6:20 | 👁 Views: 9,650

¿Listo para transformar su vida?

Contáctenos ahora para saber cómo nuestros productos pueden satisfacer sus necesidades.